Comparative statistics by cancer registry

Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site

(Shanghai, China, 1992-1995 cases followed-up until 2000)

Click on cancer site (ICD-10 code) for comparison

Site	ICD-10	No. of cases included	Complete FU		Incomplete FU: loss to FU						% with Complete FU at 5 years	Median FU (in months)
			Alive/dead	At end of FU	No.	%	% lost to FU: years from diagnosis
			No.	%	No.	%	<1	1-3	3-5	>5
C00	Lip	42	41	97.6	1	2.4	0.0	0.0	2.4	0.0	97.6	66.2
C01-02	Tongue	206	203	98.5	3	1.5	0.0	0.5	0.5	0.5	99.0	66.1
C03-06	Oral cavity	285	278	97.5	7	2.5	0.0	1.4	0.4	0.7	98.2	61.9
C07-08	Salivary gland	189	186	98.4	3	1.6	0.0	1.1	0.5	0.0	98.4	74.1
C09	Tonsil	59	56	94.9	3	5.1	3.4	1.7	0.0	0.0	94.9	47.8
C11	Nasopharynx	1060	1045	98.6	15	1.4	0.3	0.5	0.5	0.1	98.7	61.9
C12-13	Hypopharynx	37	37	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	11.8
C15	Oesophagus	2988	2980	99.7	8	0.3	0.1	0.1	0.1	0.0	99.8	6.8
C16	Stomach	11735	11656	99.3	79	0.7	0.2	0.2	0.2	0.1	99.4	9.3
C17	Small intestine	229	226	98.7	3	1.3	0.0	0.0	0.4	0.9	99.6	11.0
C18	Colon	4782	4734	99.0	48	1.0	0.1	0.3	0.4	0.2	99.2	31.4
C19-20	Rectum	3284	3249	98.9	35	1.1	0.1	0.3	0.4	0.3	99.2	32.5
C21	Anus	93	91	97.8	2	2.2	0.0	2.2	0.0	0.0	97.8	28.7
C22	Liver	6954	6942	99.8	12	0.2	0.1	0.1	0.0	0.0	99.8	3.0
C23-24	Gall bladder	1383	1378	99.6	5	0.4	0.2	0.1	0.1	0.0	99.6	3.8
C25	Pancreas	2242	2238	99.8	4	0.2	0.1	0.1	0.0	0.0	99.9	3.0
C30-31	Nose/Sinuses	200	195	97.5	5	2.5	0.5	0.5	1.0	0.5	98.0	31.4
C32	Larynx	624	621	99.5	3	0.5	0.0	0.2	0.1	0.2	99.7	56.5
C33-34	Lung	14104	14050	99.6	54	0.4	0.0	0.2	0.1	0.1	99.7	6.5
C37-38	Other thoracic organs	403	400	99.3	3	0.7	0.0	0.2	0.0	0.5	99.8	11.2
C40-41	Bone	523	520	99.4	3	0.6	0.0	0.2	0.2	0.2	99.6	8.2
C43	Melanoma skin	110	109	99.1	1	0.9	0.9	0.0	0.0	0.0	99.1	40.9
C44	Other skin	472	459	97.2	13	2.8	0.0	1.3	1.5	0.0	97.2	74.1
C47+C49	Connective tissue	482	475	98.5	7	1.5	0.1	0.8	0.4	0.2	98.8	65.4
C50	Breast	5184	5094	98.3	90	1.7	0.3	0.6	0.5	0.3	98.6	73.5
C51	Vulva	54	54	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	49.8
C52	Vagina	45	44	97.8	1	2.2	0.0	2.2	0.0	0.0	97.8	29.1
C53	Cervix	548	541	98.7	7	1.3	0.2	0.3	0.4	0.4	99.1	62.1
C54	Corpus uteri	735	725	98.6	10	1.4	0.3	0.3	0.1	0.7	99.3	76.3
C55	Uterus unspecified	145	145	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	11.6
C56	Ovary	1087	1076	99.0	11	1.0	0.2	0.4	0.2	0.2	99.2	30.2
C57	Other female genital	35	34	97.1	1	2.9	2.9	0.0	0.0	0.0	97.1	56.1
C60	Penis	49	49	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	73.6
C61	Prostate	639	634	99.2	5	0.8	0.2	0.2	0.2	0.2	99.4	25.9
C62	Testis	113	112	99.1	1	0.9	0.0	0.9	0.0	0.0	99.1	78.4
C64	Kidney	743	729	98.1	14	1.9	0.2	0.8	0.5	0.4	98.5	39.6
C65	Renal pelvis	67	67	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	61.4
C66	Ureter	68	66	97.1	2	2.9	0.0	0.0	2.9	0.0	97.1	47.3
C67	Urinary bladder	1750	1729	98.8	21	1.2	0.2	0.1	0.6	0.3	99.1	61.0
C68	Other urinary organs	26	26	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	31.6
C69	Eye	40	39	97.5	1	2.5	0.0	0.0	2.5	0.0	97.5	66.7
C70-72	Brain & nervous system	1906	1886	99.0	20	1.0	0.0	0.3	0.5	0.2	99.2	14.4
C73	Thyroid	868	841	96.9	27	3.1	0.3	1.1	1.2	0.5	97.4	77.9
C74	Adrenal gland	123	118	95.9	5	4.1	0.1	0.8	2.4	0.8	96.7	81.1
C75	Other endocrine	330	320	97.0	10	3.0	0.3	0.9	1.2	0.6	97.6	75.0
C81	Hodgkin lymphoma	99	97	98.0	2	2.0	1.0	0.0	0.0	1.0	99.0	65.5
C82-85+C96	Non-Hodgkin lymphoma	1271	1258	99.0	13	1.0	0.2	0.6	0.1	0.1	99.1	15.4
C90	Multiple myeloma	230	229	99.6	1	0.4	0.0	0.0	0.4	0.0	99.6	11.1
C91	Lymphoid leukaemia	338	338	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	13.9
C92-94	Myeloid leukaemia	605	601	99.3	4	0.7	0.0	0.2	0.3	0.2	99.5	12.4
C95	Leukaemia unspecified	377	377	100.0	0	0.0	0.0	0.0	0.0	0.0	100.0	3.6

Other tables available for this registry:

- Table1:	Data quality indices - Proportion (%) of histologically verified and death certificate only cases, number and proportion of included and excluded cases by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table2a:	Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table3:	Comparison of 1-, 3- and 5-year absolute and relative survival and 5-year age-standardized relative survival (ASRS) by site (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table4:	Site-wise number of cases, 5-year absolute and relative survival by sex and relative survival by age group (Shanghai, China, 1992-1995 cases followed-up until 2000)
- Table5:	Comparison of 5-year absolute and relative survival of cases diagnosed between 1988-1991 and 1992-1995 (Shanghai, China)

Registry chapter:

Consult the chapter in Cancer survival in developping countries (Volume II)

Cancer survival in Africa, Asia, the Caribbean and Central America (SurvCan)

Comparative statistics by cancer registry

Table2a: Number and proportion of cases with complete/incomplete follow-up and median follow-up (in months) by site